Serum M2BPGi Reliably Assesses Liver Fibrosis in Chronic Hepatitis B
Serum M2BPGi is a reliable marker for assessing liver fibrosis in patients with chronic hepatitis B virus infection.
For patients with chronic hepatitis B virus infection (CHB), serum mac-2-binding protein glycosylation isomer (M2BPGi) is a reliable marker for assessing liver fibrosis, according to results published in Clinical and Translational Gastroenterology.
M2BPGi presents a noninvasive alternative to the standard invasive liver biopsy for assessing liver fibrosis in CHB. Furthermore, M2BPGi appears to correlate well with histologic stages of liver fibrosis.
The study included participants with CBH treated with nucleos(t)ide analogues with baseline liver biopsies and retrievable serum samples (n=327). The researchers performed paired liver biopsies at 1 and 3 years.
The median M2BPGi values increased progressively with more advanced stages of liver fibrosis. The median M2BPGi was 0.26 in liver histology with Ishak F0-1, 0.34 for F2, 0.57 for F3, and 1.21 for F4 (P <.01).
The area under the receiver operator curve for serum M2BPGi was 0.653 for diagnosing ≥F2, (95% CI, 0.608-0.698, P <.001), 0.795 for diagnosing ≥F3 (95% CI, 0.743-0.848; P <.001), and 0.914 for diagnosing F4 (95% CI, 0.815-1.00, P <.001).
The researchers found that the optimal serum M2BPGi cutoff values for diagnosing ≥F2, ≥F3, and F4 were 0.25, 0.45, and 0.96, respectively.
After multivariate analysis, the researchers found that MSBPGi was the most significant independent factor for ≥F3 compared with aspartate aminotransferase to platelet ratio, aspartate aminotransferase to alanine aminotransferase ratio, and fibrosis index based on 4 factors (odds ratio, 8.197; 95% CI, 2.699-24.897; P <.001).
“Serum M2BPGi is a potential marker to conveniently diagnose F3/F4 without needing a liver biopsy,” the study authors concluded.
Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gasteroenterol. 2018;9(6):163[CM1].